Spots Global Cancer Trial Database for Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Official Title: A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer
Study ID: NCT00509665
Conditions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with doxorubicin works in treating patients with recurrent or progressive head and neck cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Contact Details
Name: Paul O'Brien
Affiliation: Medical University of South Carolina
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
